Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSO – Research Report) on April 29 and set a price target of $16.00. The company's shares closed last Friday at $2.10, close to its 52-week low of $1.89. According to TipRanks.com, Kolbert is a 1-star analyst with an average return of -2.3% and a 34.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Cytosorbents has an analyst consensus of Strong Buy, with a price target consensus of $10.25, which is a 402.5% upside from current levels.
https://www.tipranks.com/news/blurbs/dawson-james-thinks-cytosorbents-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more CytoSorbents Charts.
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more CytoSorbents Charts.